Fundamentals Hub
PALI PALISADE BIO, INC.
PALI financial statements, revenue, balance sheet, cash flow, and SEC filings
Showing 3 of 17 annual and 0 of 64 quarterly periods.
Full history available with a free account or via API.
▼ Company Profile
Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$11.20M (Jun 2025)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(858) 704-4900
EIN
522007292
Headquarters
CARLSBAD, CA, 92009
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names:
PALISADE BIO, INC. (2021–2026)
· Seneca Biopharma, Inc. (2020–2021)
· Neuralstem, Inc. (2006–2020)
▼ Key Metrics (TTM)
As of Jun 30, 2026Financials
Revenue
-
Net Income
$-31.94M
Total Assets
$127.32M
Total Equity
$121.75M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-26.2%
Return on Assets
-25.1%
Current Ratio
24.26x
Sources and calculation details
Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.
Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.
Annual (FY)
Quarterly 🔒
Chart 🔒
| Metric | FY2025 📄 | FY2024 📄 | FY2023 📄 |
|---|---|---|---|
| Income Statement | |||
| REVENUE | |||
| Revenue | $0 | $0 | $250.00K |
| OPERATING EXPENSES | |||
| R&D Expense | $10.19M | $16.00M | $6.89M |
| SG&A Expense | $7.86M | $5.80M | $6.20M |
| Operating Income | $-18.06M | $-14.86M | $-13.07M |
| NON-OPERATING INCOME / EXPENSE | |||
| Interest Expense | - | $12.00K | $15.00K |
| Other Income/Expense | $1.29M | $433.00K | $785.00K |
| Income Tax | $0 | $0 | $0 |
| Net Income | $-16.78M | $-14.44M | $-12.30M |
| PER SHARE & SUPPLEMENTAL | |||
| Diluted EPS | $-0.30 | $-10.19 | $-27.01 |
| Diluted Shares | 55.67M | 1.42M | 456.01K |
| EBITDA | $-18.05M | $-14.86M | $-13.07M |
| Depreciation & Amortization | $3.00K | $3.00K | $4.00K |
| Balance Sheet | |||
| ASSETS | |||
| Cash & Equivalents | $133.39M | $9.82M | $12.43M |
| Other Current Assets | $836.00K | $673.00K | $896.00K |
| Current Assets | $134.22M | $10.49M | $13.33M |
| PP&E (Net) | $0 | $3.00K | $10.00K |
| Other Noncurrent Assets | $68.00K | $273.00K | $490.00K |
| Noncurrent Assets | $123.00K | $386.00K | $724.00K |
| Total Assets | $134.34M | $10.88M | $14.05M |
| LIABILITIES | |||
| Accounts Payable | $767.00K | $1.11M | $698.00K |
| Other Current Liabilities | $433.00K | $243.00K | $182.00K |
| Current Liabilities | $4.64M | $3.24M | $2.59M |
| Noncurrent Liabilities | $328.00K | $152.00K | $153.00K |
| Total Liabilities | $4.96M | $3.39M | $2.74M |
| EQUITY | |||
| Common Stock | $1.59M | $27.00K | $6.00K |
| Additional Paid-in Capital | $280.51M | $143.41M | $132.81M |
| Retained Earnings | - | $135.90M | $121.50M |
| Total Equity | $129.38M | $7.49M | $11.31M |
| Total Liabilities & Equity | $134.34M | $10.88M | $14.05M |
| SUPPLEMENTAL | |||
| Shares Outstanding | 159.44M | 2.77M | 618.06K |
| Check: A − (L + E + NCI) | - | - | - |
| Cash Flow Statement | |||
| Cash from Operations | $-10.85M | $-12.19M | $-11.13M |
| Capital Expenditures | - | $0 | $4.00K |
| Cash from Investing | - | $0 | $-4.00K |
| Cash from Financing | $134.44M | $9.58M | $11.19M |
| Free Cash Flow | - | $-12.19M | $-11.14M |
| Beginning Cash (CFS) | $9.85M | $12.46M | - |
| Net Change in Cash | - | $-2.61M | - |
| Effect of FX on Cash | - | - | - |
| Calculated Ending Cash | - | $9.85M | - |
| Cash per BS | $133.39M | $9.82M | $12.43M |
| Cash scope difference (CFS − BS) | $55.00K | $26.00K | $26.00K |
| Cash per CFS | $133.44M | $9.85M | $12.46M |
Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.
Create Free Account Log In🔒
Quarterly data and charts require a free account
Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.
▼ Frequently Asked Questions
Is PALISADE BIO, INC. profitable?
No. PALISADE BIO, INC. reported $-31.94M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.